Respiratory patients are most vulnerable to the effects of climate change

A boost for di­ver­si­ty in clin­i­cal tri­als and an ear­li­er-than-ex­pect­ed $1 bil­lion spend with mi­nor­i­ty-owned busi­ness­es are some of the high­lights in Bris­tol My­ers Squibb’s

Tome Bio­sciences, a high-pro­file gene edit­ing start­up spun out of MIT, is halt­ing its lab work and look­ing to sell it­self or find a part­ner